Washington Trust Advisors, Inc. Day One Biopharmaceuticals, Inc. Transaction History
Washington Trust Advisors, Inc.
- $1.06 Billion
- Q1 2024
A detailed history of Washington Trust Advisors, Inc. transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 246 shares of DAWN stock, worth $3,372. This represents 0.0% of its overall portfolio holdings.
Number of Shares
246
Previous 246
-0.0%
Holding current value
$3,372
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding DAWN
# of Institutions
148Shares Held
60MCall Options Held
47.7KPut Options Held
61.3K-
Atlas Venture Life Science Advisors, LLC6.43MShares$88.2 Million13.29% of portfolio
-
Black Rock Inc. New York, NY5.03MShares$69 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.77MShares$65.5 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.81MShares$52.2 Million0.02% of portfolio
-
State Street Corp Boston, MA2.89MShares$39.7 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $1.01B
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...